Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lemaitre Vascular (LMAT) Cost of Revenue (2016 - 2025)

Lemaitre Vascular (LMAT) has disclosed Cost of Revenue for 16 consecutive years, with $30.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Cost of Revenue rose 689.11% to $30.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $71.1 million, a 52.05% increase, with the full-year FY2025 number at $71.1 million, up 52.05% from a year prior.
  • Cost of Revenue was $30.0 million for Q4 2025 at Lemaitre Vascular, up from $11.9 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $32.4 million in Q4 2022 to a low of -$5.1 million in Q4 2024.
  • A 5-year average of $15.0 million and a median of $13.9 million in 2021 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: crashed 132.64% in 2024, then surged 689.11% in 2025.
  • Lemaitre Vascular's Cost of Revenue stood at $13.5 million in 2021, then surged by 139.42% to $32.4 million in 2022, then tumbled by 51.85% to $15.6 million in 2023, then plummeted by 132.64% to -$5.1 million in 2024, then soared by 689.11% to $30.0 million in 2025.
  • Per Business Quant, the three most recent readings for LMAT's Cost of Revenue are $30.0 million (Q4 2025), $11.9 million (Q3 2025), and $14.9 million (Q2 2025).